Reshma Kewalramani, Vertex CEO (Barry Chin/Boston Globe via Getty Images)
April 28, 2023 12:27 PM EDTUpdated 03:10 PM
Bioregnum

An­oth­er big Ver­tex chal­lenger suf­fers a TKO. And that will cause some prob­lems for the CF champ

You al­most have to feel sor­ry for the R&D groups that try to chal­lenge Ver­tex’s $10 bil­lion cys­tic fi­bro­sis fran­chise. Even if it’s a quite …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
TRENDING NOW

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

A service from the Financial Times